Attenuated isolates of avian reoviruses associated viral arthritis/tenosynovitis in poultry are presented, including avian reovims strain 94826 C140 deposited at the ATCC under Patent Designation PTA-126077 and progeny or derivatives thereof and avian reovims strain 96139 C140 deposited at the ATCC under Patent Designation PTA-126078 and progeny or derivatives thereof. Compositions and methods for administering the isolates or compositions as vaccines to control of reovims-induced viral arthritis/tenosynovitis in birds of the order Galliformes are also presented.

The virus stabilizer is a virus stabilizer comprising a gelatin hydrolysate and an aqueous medium, wherein the virus stabilizer contains the gelatin hydrolysate at not less than 1 mass % and not more than 20 mass %, the gelatin hydrolysate has a weight average molecular weight of not more than 10000, and the gelatin hydrolysate has an isoelectric point pH of not less than 4.0 and not more than 7.0.

Attenuated G9P[6] rotavirus is disclosed herein. In some embodiments, pharmaceutical compositions are disclosed that include an attenuated G9P[6] rotavirus, or a component thereof. These compositions can be used to induce an immune response, such as a protective immune response, to a rotavirus. The compositions can be used as vaccines, such as for children (infants), for example in a prime boost strategy.

Attenuated G9P[6] rotavirus is disclosed herein. In some embodiments, pharmaceutical compositions are disclosed that include an attenuated G9P[6] rotavirus, or a component thereof. These compositions can be used to induce an immune response, such as a protective immune response, to a rotavirus. The compositions can be used as vaccines, such as for children (infants), for example in a prime boost strategy.

Attenuated G9P[6] rotavirus is disclosed herein. In some embodiments, pharmaceutical compositions are disclosed that include an attenuated G9P[6] rotavirus, or a component thereof. These compositions can be used to induce an immune response, such as a protective immune response, to a rotavirus. The compositions can be used as vaccines, such as for children (infants), for example in a prime boost strategy.

Provided herein are methods of treating cancer in a subject. The methods include administering to the subject one or more doses of an oncolytic virus (e.g., in an initial round of treatment); selecting a subject with a T-cell population exhibiting high peripheral clonality; and administering to the subject with a T-cell population exhibiting high peripheral clonality a one or more subsequent doses of the oncolytic virus (e.g., in a second round of treatment).

The present disclosure relates to one or more modified avian-virus based agents, therapies, treatments, and methods of use of the modified avian-virus based agents and/or therapies and/or treatments for cancer. The disclosure also provides for methods of generating modified avian-virus based agents.

The present disclosure relates to one or more modified avian-virus based agents, therapies, treatments, and methods of use of the modified avian-virus based agents and/or therapies and/or treatments for cancer. The disclosure also provides for methods of generating modified avian-virus based agents.

Attenuated G9P[6] rotavirus is disclosed herein. In some embodiments, pharmaceutical compositions are disclosed that include an attenuated G9P[6] rotavirus, or a component thereof. These compositions can be used to induce an immune response, such as a protective immune response, to a rotavirus. The compositions can be used as vaccines, such as for children (infants), for example in a prime boost strategy.

Attenuated G9P[6] rotavirus is disclosed herein. In some embodiments, pharmaceutical compositions are disclosed that include an attenuated G9P[6] rotavirus, or a component thereof. These compositions can be used to induce an immune response, such as a protective immune response, to a rotavirus. The compositions can be used as vaccines, such as for children (infants), for example in a prime boost strategy.